Clinico-biochemical relation of Vitamin D3 with the severity of atopic dermatitis and response to supplementation of Vitamin D3: A randomized controlled trial

The Indian journal of child health Pub Date : 2022-01-12 DOI:10.32677/ijch.v8i12.3227

N. Modi, A. Dash

{"title":"Clinico-biochemical relation of Vitamin D3 with the severity of atopic dermatitis and response to supplementation of Vitamin D3: A randomized controlled trial","authors":"N. Modi, A. Dash","doi":"10.32677/ijch.v8i12.3227","DOIUrl":null,"url":null,"abstract":"Background: Atopic dermatitis (AD), also known as eczema, is one of the most common skin disorders among children and adults, with a steep rise in diagnoses among children. Many studies have investigated the relationship between Vitamin D3 (Vit D3) and AD. Methods: A randomized controlled trial was conducted among 60 children at SCB Medical College, Cuttack from August 2014 to November 2016. Children were randomly assigned to an intervention group that received 60,000 IU of Vit. D3 every week for 6 weeks in addition to regular treatment for AD and a control group that received same treatment of AD except for Vit. D3. Both the groups were followed up at 4 weeks and 8 weeks. Results: In 60 cases of moderate to severe AD, 70% of the patients were male. About 81.7% of patients were from urban areas and 56.7% belonged to a middle socioeconomic class. In 76.6% of cases, family history of atopy was present. At baseline, mean SCORAD was 47.8±7.5 in the intervention group, and 49.2±10.3 in the control group. At baseline, serum Vitamin. D3 level (ng/ml) was 17.6±1.8 in intervention and 17.3±3.5 in control group. After Vitamin. D3 supplementation, the SCORAD improved to 12.8±5.1 (75% reduction) at 4 weeks, and 3.6±2.1 (92% reduction) at 8 weeks in the intervention group. In the control group, the mean SCORAD was 18.8±9.1 (61% reduction) at 4 weeks, and 7.3±4 (85% reduction) at 8 weeks. Discussion: The improvement of serum 25-hydroxy Vit. D3 was 134% and 366% in the intervention group compared to 78% and 121% in the observation group after 4 weeks and 8 weeks respectively. The p-values at both the time points were significant (<0.05) for the intervention group as compared to the control group. Conclusion: Short-term therapeutic supplementation of Vitamin. D3 in children with moderate to severe AD improves the clinical score. There is an inverse relationship between serum Vitamin. D3 level and severity of AD.","PeriodicalId":22476,"journal":{"name":"The Indian journal of child health","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Indian journal of child health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32677/ijch.v8i12.3227","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Atopic dermatitis (AD), also known as eczema, is one of the most common skin disorders among children and adults, with a steep rise in diagnoses among children. Many studies have investigated the relationship between Vitamin D3 (Vit D3) and AD. Methods: A randomized controlled trial was conducted among 60 children at SCB Medical College, Cuttack from August 2014 to November 2016. Children were randomly assigned to an intervention group that received 60,000 IU of Vit. D3 every week for 6 weeks in addition to regular treatment for AD and a control group that received same treatment of AD except for Vit. D3. Both the groups were followed up at 4 weeks and 8 weeks. Results: In 60 cases of moderate to severe AD, 70% of the patients were male. About 81.7% of patients were from urban areas and 56.7% belonged to a middle socioeconomic class. In 76.6% of cases, family history of atopy was present. At baseline, mean SCORAD was 47.8±7.5 in the intervention group, and 49.2±10.3 in the control group. At baseline, serum Vitamin. D3 level (ng/ml) was 17.6±1.8 in intervention and 17.3±3.5 in control group. After Vitamin. D3 supplementation, the SCORAD improved to 12.8±5.1 (75% reduction) at 4 weeks, and 3.6±2.1 (92% reduction) at 8 weeks in the intervention group. In the control group, the mean SCORAD was 18.8±9.1 (61% reduction) at 4 weeks, and 7.3±4 (85% reduction) at 8 weeks. Discussion: The improvement of serum 25-hydroxy Vit. D3 was 134% and 366% in the intervention group compared to 78% and 121% in the observation group after 4 weeks and 8 weeks respectively. The p-values at both the time points were significant (<0.05) for the intervention group as compared to the control group. Conclusion: Short-term therapeutic supplementation of Vitamin. D3 in children with moderate to severe AD improves the clinical score. There is an inverse relationship between serum Vitamin. D3 level and severity of AD.

查看原文本刊更多论文

维生素D3与特应性皮炎严重程度的临床生化关系及补充维生素D3的反应:一项随机对照试验

背景:特应性皮炎(AD)，也称为湿疹，是儿童和成人中最常见的皮肤病之一，儿童的诊出率急剧上升。许多研究调查了维生素D3 (Vit D3)和AD之间的关系。方法:对2014年8月至2016年11月在卡塔克SCB医学院就读的60名儿童进行随机对照试验。儿童被随机分配到接受60000国际单位维生素d的干预组。在常规治疗AD的基础上，每周服用D3，持续6周，对照组接受除Vit外的相同治疗。D3。两组分别于第4周和第8周随访。结果:60例中重度AD患者中，男性占70%。约81.7%的患者来自城市地区，56.7%的患者属于中等社会经济阶层。76.6%的病例有特应性家族史。在基线时，干预组的平均SCORAD为47.8±7.5，对照组为49.2±10.3。在基线，血清维生素。干预组D3水平(ng/ml)为17.6±1.8，对照组为17.3±3.5。维生素。补充D3后，干预组的SCORAD在4周时改善至12.8±5.1(降低75%)，在8周时改善至3.6±2.1(降低92%)。对照组的平均SCORAD在4周时为18.8±9.1(降低61%)，在8周时为7.3±4(降低85%)。讨论:提高血清25-羟基Vit。干预组D3在4周和8周后分别为134%和366%，观察组为78%和121%。与对照组相比，干预组在两个时间点的p值均有显著性差异(<0.05)。结论:短期治疗性补充维生素。中度至重度AD患儿服用D3可提高临床评分。血清中维生素含量呈反比关系。D3水平和AD的严重程度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Indian journal of child health

自引率

0.00%

发文量